News
05-21-2010, 06:50 AM
ARIAD Pharmaceuticals, Inc. today announced that new data on AP24534, its investigational pan-BCR-ABL inhibitor, and ridaforolimus, its investigational mTOR inhibitor being developed by Merck, Sharpe & Dohme Corp., have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting.
More... (http://www.news-medical.net/news/20100521/New-data-on-ARIADs-AP24534-and-ridaforolimus-accepted-for-presentation-at-ASCO-2010.aspx)
More... (http://www.news-medical.net/news/20100521/New-data-on-ARIADs-AP24534-and-ridaforolimus-accepted-for-presentation-at-ASCO-2010.aspx)